Top 100 Drugs in Canada

Canadian Healthcare Network
1 of 25
http://www.canadianhealthcarenetwork.ca/pharmacists/news/special-repo...
Top 100 Drugs

on March 4, 2013 for Pharmacy Practice
witnessed a year of increased prescription volume fueled by generic prescription growth and brand patent
expiries
Prescription volume continued to increase in 2012, fueled by increased

access to generics, an aging population, and the prevalence of chronic
diseases (Figure 1). As they did last year, specialty and niche prescription
products are having an impact on the market. In the 12 months ending
October 2012, community pharmacies across Canada dispensed almost 557
million prescriptions, an increase of 3.3% over 2011. The growing
penetration of lower-cost generics continues to drive todays deflationary
market. For the fifth consecutive year, generic prescription products
continued to dominate the prescription market, comprising 62.6% of the
total market. Brand prescriptions share continued to fall (at 37.4% of the
total market, down from 40.2% last year). Thats a decrease of 3.5%, a
further slowdown from last years -1.6%. Generic prescription volume grew
by 8.2%, down 2.4 percentage points from the rate posted in the
prior-year period10.6%. (See Tables 1, 2, and 3 for the top 100
prescription drugs of 2012.)
The continuing gains in generic prescription market share can be attributed
to patent expiries and to public- and private-sector policies reimbursing
lower-cost drug alternatives.
About IMS Brogan

The information for this article
was obtained from three of IMS
Brogans databases: Canadian
CompuScript Audit (CS),
Canadian Drugstore and Hospital
Purchases Audit (CDH), and
Canadian Disease and
Therapeutic Index (CDTI), as
well as from the PharmaFocus
2016 update, published
November 2012. IMS Brogan is
a unit of IMS, the worlds leading
provider of market intelligence
to the pharmaceutical and
healthcare industries.
For example, Crestor lost its patent exclusivity to seven generic copies in April 2012. The market started to feel
the impact in June, and Crestors prescription share continued to tumble all year. Other major brands that lost
exclusivity, contributing to a slower brand performance, included Plavix (December 2011), Singulair (October
2011), Micardis and Micardis Plus (January 2012), Cellcept (November 2011), Cozaar (January 2012), Cesamet
(March 2012), and Hyzaar and Hyzaar DS (January 2012).
Generic substitution erodes brand prescription share

The generic price reductions implemented in most provinces will continue to be phased in between 2012 and
2014, further dampening potential brand growth.
On the private-payer side, two major insurance companies, Sun Life and Great-West Life, instituted new policies
in 2012 to reject claims for brand medicines when a generic is available. Together, these insurers administer
about half of Canadas private drug plans. Other companies, such as Manulife, are planning on adopting similar
programs.
Top therapeutic classes
12/03/2013 8:14 AM
2 of 25
Click for larger view

For the 19th consecutive year, cardiovascular medications were the most prescribed class, with a total of 83.4
million prescriptions dispensed, valued at $2.6 billion. This corresponds well to the top reason for patients to
visit a family physician (see sidebar on page 41). Unchanged from last year, the top 10 drug classes represent
69.7% of total dispensed prescriptions and 63.3% of total prescription dollar value (Table 4).
In each of the top 10 therapeutic categories, significantly more prescriptions were written for generic
medications than for brand medicines, most notably in the cardiovasculars, psychotherapeutics, anti-infectives,
and diuretics classes. The fastest-growing (35.7%) prescription drug class is anti-EGFR (anti-epidermal growth
factor receptor) agents, used in the treatment of advanced cancers. Anti-EGFRs bumped ophthalmologic
preparations out of the top spot after three years as the highest growth class, with total purchases of at least
$10 million annually made by community and hospital pharmacies. The EGFR class of drugs has become a
foundation in the treatment of many common cancers, targeting the specific type of cancer. Targeted agents are
the foundation for the future of cancer treatment as they provide a less toxic treatment regimen, allowing
patients to have a chance of receiving the optimal doses over longer periods of time.
Conversely, cytostatic antibiotics used in cancer therapy experienced the largest decrease in purchases for the
12 months ending October 2012 (-41.7%). The reason for the decline of this group of drugs may in fact be due
to novel classes of newer, targeted anticancer drugs that are more efficient, less toxic, and cause less severe
side effects.
Most prescribed products

Looking at the top 100 Rx Drugs, the top four products remain unchanged from last year (Table 1). Synthroid
retained the top spot for a third year with 14.7 million prescriptions dispensed for the 12 months ending
October 2012. Crestor stayed in second place, despite a 24.3% drop due to generic competition.
12/03/2013 8:14 AM
3 of 25

Cipralex, the selective serotonin reuptake inhibitor, jumped up from 22nd position in 2011 to seventh in 2012
due to formulary listing in major provinces such as British Columbia, Alberta, and Ontario. Elavil also moved
into the top 10, up from 16th place. After losing patent protection, Plavix dropped from 7th spot to 48th.
Of the top 100 products, 63 are generic and 37 are brand. Those 63 generics represent 47.4% of total
prescriptions dispensed for the top 100 products. Twenty-two of these products are manufactured by Apotex,
16 by Teva, nine by Pharmascience, and four by Pro Doc. Seven other manufacturers produce the remaining 12
generics.
Prescription sales dollars

The top 100 products based on prescription dollars represented 45.3% of all prescription expenditures for the
12 months ending October 2012 (Table 5). Crestor remains at the top of the list in spite of a 27.3% drop. Brand
purchases totaled $13.95 billion for the 12 months ending October 2012 and accounted for 75.9% of the
market, up a bit from last years 75.7%. Brand sales grew by 0.6%, a positive change from the 0.4% decrease
noted a year ago. The generic sector accounted for the remaining 24.1% of market sales, down slightly from
24.3% a year ago, at $4.4 billion. Generic purchases posted negative growth of -0.5%, a noted improvement
over the -5.3% pace recorded a year ago.
Figure 2 highlights percentage growth of drugstore and hospital drug purchases over the past five years.
A history of the top five products

The top five Rx products provide further evidence of the impact that our aging population
has, and will continue to have, on prescription medications. Four out of the top five treat
various cardiovascular conditions, while the top drug, Synthroid treats hypothyroidism.
Abbott EPDs Synthroid (levothyroxine) is a prescription synthetic thyroid hormone that

was introduced in 1957. It is typically taken for life.
Crestor (rosuvastatin), produced by AstraZeneca, is a member of the statin class for

the treatment of dyslipidemia. It reduces LDL-C and raises HDL-C. Crestor was initially
developed by the Japanese pharmaceutical company Shionogi and in-licensed to
AstraZeneca in April 1998. It was launched in Canada in 2003.
The first of Apotexs two products in the overall top five, Apo-atorvastatin launched in
2010 as a lower-cost alternative to Pfizers Lipitor.
The second, Apo-furosemide launched in 1976 as a diuretic primarily used for the treatment
of hypertension and edema associated with congestive heart failure and kidney or
liver disease.
In 1994, Servier launched the ACE inhibitor Coversyl (perindopril) in Canada. It is indicated
to treat mild to moderate hypertension, mild to moderate congestive heart failure,
and to reduce cardiovascular risk in patients with hypertension and/or those who have
suffered a myocardial infarction.
Top generic products

Looking at the top 100 generic products only, Apo-atorvastatin is again the top product in terms of volume,
with close to 5.5 million prescriptions (Table 2). Figure 3a reveals the breakdown of brand versus generic sales
for the drug oxycodone. In February 2012, Purdue launched OxyNEO, a new abuse-deterrent formulation of
oxycodone to replace Purdues OxyContin. OxyNEO is leading the way in oxycodone sales with just over $1
12/03/2013 8:14 AM
4 of 25
million due in part to public formulary listings in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario
(except for 60 mg strength), and Quebec. OxyNEO is funded through the Special or Exceptional Access Program
in the majority of provinces, except in Alberta where it is funded as a full benefit. (Market share data for
esomeprazole, rosuvastatin, atorvastatin, and pantoprazole are available online [Figure 3be]). Apotex claimed
30 of the top 100 generic products, with Teva close behind at 25 products.
Diagnosis
*Estimated number
of diagnosed
patient visits (000s)
HYPERTENSION
19,773
routine general medical exam
10,369
diabetes
9,759
depression
8,324
anxiety
6,313
normal pregnancy supervision
5,357
acute upper respiratory

infection
5,302
hyperlipidemia
4,370
esophagitis
3,831
otitis media
3,415
Most prescribed by generic name

Atorvastatin and levothyroxine retain the top two spots, with some shuffling among the rest of the top 10
(Table 3). The only new entrant, moving up from 11th to 10th place is lorazepam. The top 100 drugs (by
generic name) represent 70.6% of the total dispensed prescriptions.
table 1. Top 100 Rx drugs
2012
2011
PRODUCT
MANUFACTURER
12
months
ending
Oct.
2012
%
CHANGE
vs 12
months
ending
12/03/2013 8:14 AM
5 of 25
TRx*
(000s)
Oct.
2011
Synthroid
ABBOTT EPD
14,709
7.6
Crestor
ASTRAZENECA
8,423
-24.3
Apo-atorvastatin
APOTEX
5,485
0.4
Apo-furosemide
APOTEX
4,084
3.6
Coversyl
SERVIER LAB
3,759
16.5
Apo-hydro
APOTEX
3,197
-6.5
22
Cipralex
LUNDBECK
CANADA
3,151
29.3
Teva-amoxicillin
TEVA CANADA
3,134
-14.9
Nexium
ASTRAZENECA
3,107
-18.6
10
16
Elavil
AA PHARMA
3,007
14.6
11
15
Taro-warfarin
TARO PHARM
2,855
6.2
12
11
Ativan
PFIZER
2,854
1.4
13
23
Lyrica
PFIZER
2,848
17.3
14
13
Celebrex
PFIZER
2,699
-1.4
15
32
Zyloprim
AA PHARMA
2,675
25.9
16
47
Teva-venlafaxine XR
TEVA CANADA
2,670
51.9
17
12
Ventolin HFA
GLAXOSMITHKLINE
2,663
-5.2
18
57
D-tabs
RIVA
2,605
59.9
19
27
Apo-salvent CFC FR
APOTEX
2,475
11
20
10
Apo-ramipril
APOTEX
2,475
-15.7
21
18
Eltroxin
TRITON PHARMA
2,441
-3.3
22
19
Apo-lorazepam
APOTEX INC
2,391
-3.9
12/03/2013 8:14 AM
6 of 25
23
26
Nasonex
MERCK CANADA
2,274
1.4
24
24
Ratio-lenoltec
TEVA CANADA
2,250
-2.1
25
34
Ezetrol
MERCK CANADA
2,215
26
21
Ran-atorvastatin
RANBAXY PHARMA
2,211
-10.1
27
25
Ratio-oxycocet
TEVA CANADA
2,164
-4.4
28
37
Ratio-metformin
TEVA CANADA
2,154
11.3
29
128
Ratio-atorvastatin
TEVA CANADA
2,136
124.7
30
33
Pro-AAS EC-80
PRO DOC
2,132
4.6
31
40
Apo-metformin
APOTEX
2,096
12.7
32
31
Flovent HFA
GLAXOSMITHKLINE
2,090
-1.7
33
29
Tylenol w/cod #3
JANSSEN PHARMA
2,027
-7
34
20
Teva-rabeprazole
TEVA CANADA
1,995
-19.5
35
36
Adalat XL
BAYER
HEALTHCARE
1,992
1.7
36
35
Teva-furosemide
TEVA CANADA
1,987
-1.8
37
107
Tecta
NYCOMED CANADA
1,962
86.3
38
41
Spiriva
BOEHRINGER ING
1,937
5.2
39
63
Ran-ramipril
RANBAXY PHARMA
CAN
1,907
24.5
40
39
Apo-metoprolol
APOTEX
1,903
0.5
41
131
Apo-bisoprolol
APOTEX
1,902
102.1
42
49
Aricept
PFIZER
1,887
8.6
43
48
Alesse
PFIZER
1,857
6.4
44
60
Wellbutrin XL
VALEANT PHARMA
1,852
16.3
45
56
pms-Clonazepam-R
PHARMASCIENCE
1,846
11.3
12/03/2013 8:14 AM
7 of 25
46
69
Atorvastatin
PRO DOC
1,841
25
47
14
Sandoz-bisoprolol
SANDOZ CANADA
1,810
-32.8
48
Plavix
BMS-SANOFI
1,808
-50.7
49
72
pms-Amlodipine
PHARMASCIENCE
1,808
25.5
50
45
Apo-oxazepam
APOTEX
1,796
-0.4
51
44
pms-Hydrochlorothiazide
PHARMASCIENCE
1,768
-2.3
52
30
Teva-hydrochlorothiazide
TEVA CANADA
1,716
-20.1
53
50
Toloxin
PENDOPHARM
1,704
-1.5
54
61
Ran-pantoprazole
RANBAXY PHARMA
CAN
1,652
5.2
55
38
Apo-citalopram
APOTEX
1,643
-13.4
56
71
Teva-pantoprazole
TEVA CANADA
1,587
10
57
91
Apo-amoxi
APOTEX
1,581
30.5
58
66
Apo-amlodipine
APOTEX
1,575
5.3
59
55
Apo-lansoprazole
APOTEX
1,559
-6.1
60
52
Coumadin
BMS PHARMA
1,557
-9.1
61
70
Symbicort
ASTRAZENECA
1,544
5.3
62
67
One Touch Ultra
LIFESCAN
1,511
1.1
63
101
Cymbalta
LILLY
1,500
31.4
64
65
Apo-naproxen
APOTEX
1,495
-0.6
65
87
pms-Citalopram
PHARMASCIENCE
1,467
14.1
66
97
Seroquel XR
ASTRAZENECA
1,457
23.3
67
43
Teva-risedronate
TEVA CANADA
1,452
-20.1
68
83
Pro-metformin
PRO DOC
1,427
6.9
12/03/2013 8:14 AM
8 of 25
69
79
Teva-amlodipine
TEVA CANADA
1,417
3.8
70
122
pms-Ramipril
PHARMASCIENCE
1,393
43.2
71
68
Co Metformin
COBALT PHARMA
1,383
-6.9
72
82
Ascensia microfill
BAYER
HEALTHCARE
1,382
73
76
Advair diskus
GLAXOSMITHKLINE
1,381
-0.6
74
104
Teva-trazodone
TEVA CANADA
1,364
27.6
75
46
Lipitor
PFIZER
1,361
-23.5
76
222
Sandoz-valsartan
SANDOZ CANADA
1,353
131.2
77
62
Teva-lorazepam
TEVA CANADA
1,345
-12.4
78
5568
Apo-clopidogrel
APOTEX
1,335
******
79
75
Teva-metoprolol
TEVA CANADA
1,335
-4.6
80
81
Apo-pantoprazole
APOTEX
1,326
-1.2
81
77
Teva-olanzapine
TEVA CANADA
1,324
-3.5
82
73
Apo-prednisone
APOTEX
1,312
-7.9
83
80
Diamicron MR
SERVIER LAB
1,312
-2.5
84
86
Apo-metoprolol-L
APOTEX
1,288
-1.1
85
84
Mylan-nifedipine
MYLAN PHARMA
1,271
-4.3
86
92
Atorvastatin
SANIS HEALTH
1,264
6.5
87
98
pms-Clonazepam
PHARMASCIENCE
1,263
6.9
88
334
Apo-esomeprazole
APOTEX
1,262
231.2
89
274
Sandoz-tamsulosin
SANDOZ CANADA
1,262
168.7
90
114
Apo-trazodone
APOTEX
1,255
22.3
91
94
Premarin
PFIZER
1,254
5.9
12/03/2013 8:14 AM
9 of 25
92
127
pms-Atenolol
PHARMASCIENCE
1,251
30.8
93
105
Avodart
GLAXOSMITHKLINE
1,251
18.5
94
64
Yasmin
BAYER
HEALTHCARE
1,243
-18.7
95
100
pms-Zopiclone
PHARMASCIENCE
1,235
7.9
96
117
pms-Metoprolol-L
PHARMASCIENCE
1,232
21.9
97
78
Apo-omeprazole
APOTEX
1,230
-10
98
149
Januvia
MERCK CANADA
1,226
42.2
99
96
Estrace
SHIRE CANADA
1,218
100
112
Amlodipine
PRO DOC
1,201
15.7
*Estimated volume of prescriptions dispensed from Canadian retail pharmacies. Source: IMS Brogan, Canadian
CompuScript,12 months ending October 2012.
Due to routine data history corrections completed in 2012, certain product rankings listed in the Feb/March
2012 issue of Pharmacy Practice may differ from those listed above.
table 2. Top 100 generic Rx products
12
months
ending
Oct.
2012
TRx*
(000s)
RANK
PRODUCT
%
CHANGE
vs 12
months
ending
Oct. 2011
MANUFACTURER
Apo-atorvastatin
APOTEX
5,485
0.4
Apo-furosemide
APOTEX
4,084
3.6
Apo-hydro
APOTEX
3,197
-6.5
Teva-amoxicillin
TEVA CANADA
3,134
-14.9
Elavil
AA PHARMA
3,007
14.6
12/03/2013 8:14 AM
10 of 25
Taro-warfarin
TARO
PHARMACEUTICA
2,855
6.2
Zyloprim
AA PHARMA
2,675
25.9
Teva-venlafaxine
TEVA CANADA
2,670
51.9
D-tabs
RIVA
2,605
59.9
10
Apo-salvent CFC FR
APOTEX
2,475
11
11
Apo-ramipril
APOTEX
2,475
-15.7
12
Apo-lorazepam
APOTEX
2,391
-3.9
13
Ratio-lenoltec #3
TEVA CANADA
2,250
-2.1
14
Ran-atorvastatin
RANBAXY PHARMA
CAN
2,211
-10.1
15
Ratio-oxycocet
TEVA CANADA
2,164
-4.4
16
Ratio-metformin
TEVA CANADA
2,154
11.3
17
Ratio-atorvastatin
TEVA CANADA
2,136
124.7
18
Pro-AAS EC-80
PRO DOC
2,132
4.6
19
Apo-metformin
APOTEX
2,096
12.7
20
Teva-rabeprazole
TEVA CANADA
1,995
-19.5
21
Teva-furosemide
TEVA CANADA
1,987
-1.8
22
Ran-ramipril
RANBAXY PHARMA
CAN
1,907
24.5
23
Apo-metoprolol
APOTEX
1,903
0.5
24
Apo-bisoprolol
APOTEX
1,902
102.1
25
pms-Clonazepam-R
PHARMASCIENCE
1,846
11.3
26
Atorvastatin
PRO DOC
1,841
25
27
Sandoz-bisoprolol
SANDOZ CANADA
1,810
-32.8
28
pms-Amlodipine
PHARMASCIENCE
1,808
25.5
12/03/2013 8:14 AM
11 of 25
29
Apo-oxazepam
APOTEX
1,796
-0.4
30
pms-Hydrochlorothiazide
PHARMASCIENCE
1,768
-2.3
31
Teva-hydrochlorothiazide
TEVA CANADA
1,716
-20.1
32
Ran-pantoprazole
RANBAXY PHARMA
CAN
1,652
5.2
33
Apo-citalopram
APOTEX
1,643
-13.4
34
Teva-pantoprazole
TEVA CANADA
1,587
10
35
Apo-amoxi
APOTEX
1,581
30.5
36
Apo-amlodipine
APOTEX
1,575
5.3
37
Apo-lansoprazole
APOTEX
1,559
-6.1
38
Apo-naproxen
APOTEX
1,495
-0.6
39
pms-Citalopram
PHARMASCIENCE
1,467
14.1
40
Teva-risedronate
TEVA CANADA
1,452
-20.1
41
Pro-metformin
PRO DOC
1,427
6.9
42
Teva-amlodipine
TEVA CANADA
1,417
3.8
43
pms-Ramipril
PHARMASCIENCE
1,393
43.2
44
Co metformin
COBALT PHARMA
1,383
-6.9
45
Teva-trazodone
TEVA CANADA
1,364
27.6
46
Sandoz-valsartan
SANDOZ CANADA
1,353
131.2
47
Teva-lorazepam
TEVA CANADA
1,345
-12.4
48
Apo-clopidogrel
APOTEX
1,335
******
49
Teva-metoprolol
TEVA CANADA
1,335
-4.6
50
Apo-pantoprazole
APOTEX
1,326
-1.2
51
Teva-olanzapine
TEVA CANADA
1,324
-3.5
12/03/2013 8:14 AM
12 of 25
52
Apo-prednisone
APOTEX
1,312
-7.9
53
Apo-metoprolol-L
APOTEX
1,288
-1.1
54
Mylan-nifedipine XR
MYLAN PHARMA
1,271
-4.3
55
Atorvastatin
SANIS HEALTH
1,264
6.5
56
pms-Clonazepam
PHARMASCIENCE
1,263
6.9
57
Apo-esomeprazole
APOTEX
1,262
231.2
58
Sandoz-tamsulosin
SANDOZ CANADA
1,262
168.7
59
Apo-trazodone
APOTEX
1,255
22.3
60
pms-Atenolol
PHARMASCIENCE
1,251
30.8
61
pms-Zopiclone
PHARMASCIENCE
1,235
7.9
62
pms-Metoprolol-L
PHARMASCIENCE
1,232
21.9
63
Apo-omeprazole
APOTEX
1,230
-10
64
Amlodipine
PRO DOC
1,201
15.7
65
Apo-cephalex
APOTEX
1,195
26.2
66
Teva-spironolactone
TEVA CANADA
1,169
21
67
pms-Hydromorphone
PHARMASCIENCE
1,158
17.6
68
Taro-docusate
TARO
PHARMACEUTICA
1,148
25.7
69
Apo-rosuvastatin
APOTEX
1,133
******
70
Teva-ramipril
TEVA CANADA
1,115
-33
71
Teva-salbutamol HFA
TEVA CANADA
1,102
7.8
72
Apo-zopiclone
APOTEX
1,094
23.3
73
Pantoprazole
PRO DOC
1,078
22.7
74
Sandoz-pantoprazole
SANDOZ CANADA
1,077
36.2
12/03/2013 8:14 AM
13 of 25
75
Apo-temazepam
APOTEX
1,068
21.7
76
Gliclazide MR
AA PHARMA
1,059
67.9
77
Calcite 500+D 400
RIVA
1,043
-15.6
78
Ratio-venlafaxine
TEVA CANADA
1,029
-53.3
79
pms-Atorvastatin
PHARMASCIENCE
1,019
19.1
80
Mylan-metformin
MYLAN PHARMA
1,009
-12.3
81
Apo-candesartan
APOTEX
1,007
277.2
82
Teva-divalproex
TEVA CANADA
993
83
Apo-quetiapine
APOTEX
986
19.3
84
pms-Docusate sodium
PHARMASCIENCE
979
33
85
Apo-ibuprofen
APOTEX
939
-2.3
86
pms-Metformin
PHARMASCIENCE
939
6.4
87
Ran-rabeprazole
RANBAXY PHARMA
CAN
935
-21.1
88
Teva-prednisone
TEVA CANADA
922
23.8
89
Teva-rosuvastatin
TEVA CANADA
915
******
90
Sandoz-valsartan HCT
SANDOZ CANADA
910
134.3
91
Jamp-vitamin D3
JAMP PHARMA
909
108.7
92
Betaderm
TARO
PHARMACEUTICA
908
40.8
93
Metformin
SANIS HEALTH
902
89.3
94
pms-Quetiapine
PHARMASCIENCE
897
15.8
95
Sandoz-rabeprazole
SANDOZ CANADA
896
77.8
96
Mylan-zopiclone
MYLAN PHARMA
882
6.6
97
Teva-glyburide
TEVA CANADA
874
-3.5
12/03/2013 8:14 AM
14 of 25
98
Euro-fer
EUROPHARM
873
10.1
99
Ratio-domperidone
TEVA CANADA
864
26.6
100
Apo-acetaminophen
APOTEX
861
-11.1
table 3. Top 100 Rx drugs (by generic name)
% CHANGE
vs 12 months
ending Oct.
2011
12 months
ending Oct.
2012
TRx* (000s)
2012
2011
GENERIC NAME
ATORVASTATIN
17,240
0.7
LEVOTHYROXINE
17,150
5.9
ROSUVASTATIN
12,523
12.6
METFORMIN
12,508
2.7
PANTOPRAZOLE
11,051
17.3
AMLODIPINE
10,374
5.6
RAMIPRIL
9,375
-1.9
METOPROLOL
7,806
4.2
10
FUROSEMIDE
7,711
3.7
10
11
LORAZEPAM
7,331
-1.2
11
12
CITALOPRAM
7,302
0.8
12
HYDROCHLOROTHIAZIDE
7,250
-8.5
13
15
QUETIAPINE
6,985
9.9
14
13
VENLAFAXINE
6,706
12/03/2013 8:14 AM
15 of 25
15
14
SALBUTAMOL
6,641
2.8
16
23
CHOLECALCIFEROL
6,260
38.5
17
16
AMOXICILLIN
5,625
-4.3
18
17
WARFARIN
5,620
-3.1
19
18
ACETAMINOPHEN &
CAFFEINE & CODEINE
5,319
-4.4
20
20
ZOPICLONE
5,283
21
21
DOCUSATE
5,255
7.9
22
19
CLONAZEPAM
5,148
3.3
23
25
BISOPROLOL
4,968
12.8
24
22
RABEPRAZOLE SODIUM
4,550
-5.3
25
26
ESOMEPRAZOLE
4,370
4.1
26
29
TRAZODONE
4,014
8.1
27
30
CLOPIDOGREL
3,795
3.4
28
31
IRON FERROUS
3,774
6.4
29
39
PERINDOPRIL
3,759
16.5
30
34
ETHINYL ESTRADIOL &

LEVONORGESTREL
3,616
31
28
ATENOLOL
3,607
-3.5
32
33
NAPROXEN
3,551
0.4
33
36
FLUTICASONE
3,430
0.4
34
32
RISPERIDONE
3,425
-3.2
35
43
TAMSULOSIN
3,376
8.7
36
24
CALCIUM &
ERGOCALCIFEROL
3,359
-24.3
37
35
RISEDRONATE
3,334
-3.1
12/03/2013 8:14 AM
16 of 25
38
41
ACETAMINOPHEN
3,317
4.6
39
37
NIFEDIPINE
3,273
-0.7
40
57
CALCIUM
3,171
24.2
41
64
ESCITALOPRAM
3,151
29.3
42
38
OMEPRAZOLE
3,134
-4.5
43
45
AMITRIPTYLINE
3,127
2.6
44
40
LANSOPRAZOLE
3,074
-4.2
45
44
DILTIAZEM
3,054
-0.1
46
47
MOMETASONE
3,026
47
54
GLICLAZIDE
3,025
15.1
48
42
SIMVASTATIN
2,969
-5.9
49
56
HYDROMORPHONE
2,933
14.8
50
66
PREGABALIN
2,848
17.3
51
61
GABAPENTIN
2,837
15.5
52
46
IRBESARTAN
2,703
-10.5
53
58
ALLOPURINOL
2,700
6.3
54
50
CELECOXIB
2,699
-1.4
55
49
ACETAMINOPHEN &
OXYCODONE
2,694
-5.3
56
62
BUPROPION
2,680
9.3
57
48
ALENDRONATE
2,642
-7.9
58
52
OXAZEPAM
2,620
-1.1
59
59
ACETYLSALICYLIC ACID
2,562
2.9
60
65
PREDNISONE
2,549
4.9
12/03/2013 8:14 AM
17 of 25
61
55
OLANZAPINE
2,542
-3.2
62
53
PAROXETINE
2,524
-4.5
63
73
METHYLPHENIDATE
2,504
9.4
64
68
ESTRADIOL
2,494
4.6
65
51
GLYBURIDE
2,450
-7.7
66
60
VALSARTAN
2,443
-0.5
67
75
SERTRALINE
2,375
7.1
68
63
RANITIDINE
2,363
-3.2
69
76
CANDESARTAN
2,328
7.3
70
71
CIPROFLOXACIN
2,294
-1
71
69
DOMPERIDONE
2,287
-2.9
72
74
FLUTICASONE &
SALMETEROL
2,264
1.3
73
80
EZETIMIBE
2,215
74
67
OXYCODONE
2,213
-7.8
75
72
CLARITHROMYCIN
2,159
-6
76
79
DIVALPROEX
2,107
77
77
ETHINYL ESTRADIOL &

NORGESTIMATE
2,070
-2.8
78
82
POTASSIUM
2,053
2.8
79
70
DROSPIRENONE &
ETHINYL ESTRADIOL
2,043
-13
80
83
AZITHROMYCIN
2,028
1.8
81
81
DICLOFENAC
2,021
0.9
82
85
MIRTAZAPINE
2,017
9.9
83
78
CYANOCOBALAMIN
1,999
-2.7
12/03/2013 8:14 AM
18 of 25
84
84
TIOTROPIUM BROMIDE
1,937
5.2
85
87
DONEPEZIL
1,893
8.7
86
91
HYDROCORTISONE
1,833
9.7
87
93
MORPHINE
1,796
9.2
88
97
SENNOSIDES A&B
1,751
10.8
89
89
CYCLOBENZAPRINE
1,744
2.7
90
94
TELMISARTAN
1,735
7.2
91
95
CEPHALEXIN
1,715
6.5
92
86
DIGOXIN
1,709
-2.7
93
96
BETAMETHASONE
1,676
5.4
94
88
HYDROCHLOROTHIAZIDE
& VALSARTAN
1,657
-3.1
95
90
TEMAZEPAM
1,638
-2.5
96
92
NITROGLYCERIN
1,582
-4.6
97
102
BUDESONIDE &
FORMOTEROL
1,544
5.3
98
117
DULOXETINE
1,500
31.4
99
100
FENOFIBRATE
1,491
-1.2
100
98
FOLIC ACID
1,453
-6
Due to routine data history corrections completed in 2012, certain product rankings listed in the Feb/March
2012 issue of Pharmacy Practice may differ from those listed above.
table 4. Top 10 classes
RANK
THERAPEUTIC CLAS
TRx* 12
MONTHS
TRx %
Change
TRx $$**
12
12/03/2013 8:14 AM
19 of 25
ENDING OCT
RANK
THERAPEUTIC
CLAS 2012
(000s)
Over 12
MONTHS
ENDING
OCT
2011
MONTHS
ENDING
OCT
2012
(000s)
CARDIOVASCULARS
83,447
2.7
$2,645,107
psychotherapeutics
73,714
4.5
$2,635,579
gastrointestinal/genitourinary
41,718
5.3
$1,767,847
antihyperlipidemic agents
38,598
$1,885,270
analgesics
28,622
1.6
$1,109,556
hormones
27,129
1.2
$1,018,726
anti-infectives
24,628
-1.4
$887,483
diabetes therapy
26,166
4.8
$1,211,700
neurological disorders
25,123
6.4
$1,252,671
10
diuretics
18,926
-1.9
$194,904
*Estimated volume of prescriptions dispensed in Canadian retail pharmacies.

**Estimated dollar value of prescriptions dispensed from Canadian retail pharmacies (includes professional fees
and mark-ups).
Source: IMS Brogan, Canadian CompuScript
12/03/2013 8:14 AM
20 of 25
table 5. Top 100 products based on prescription dollars
12/03/2013 8:14 AM
21 of 25
RANK
PRODUCT NAME
12
months
ending
Oct. 2012
TRx*
(000s)
%
CHANGE
vs 12
months
ending
Oct. 2011
MANUFACTURER
CRESTOR
ASTRAZENECA
$634,357
-27.3
REMICADE
JANSSEN PHARMA
$541,183
6.5
HUMIRA
ABBOTT SPD
$399,051
23.6
ENBREL
AMGEN
$329,854
8.1
CIPRALEX
LUNDBECK CANADA
$259,878
29.7
LYRICA
PFIZER
$258,602
14.8
NEXIUM
ASTRAZENECA
$257,173
-23.9
ADVAIR DISKUS
GLAXOSMITHKLINE
$226,686
0.6
SPIRIVA
BOEHRINGER ING
$206,320
6.8
10
EZETROL
MERCK CANADA
$202,061
8.3
11
CYMBALTA
LILLY
$191,242
30.5
12
APO-ATORVASTATIN
APOTEX
$188,600
-9.6
13
COVERSYL
SERVIER LAB
$187,140
17.5
14
SYMBICORT
ASTRAZENECA
$185,766
8.6
15
CELEBREX
PFIZER
$185,458
-0.5
16
SYNTHROID
ABBOTT EPD
$168,886
8.6
17
FLOVENT HFA
GLAXOSMITHKLINE
$163,658
-1
18
ARICEPT
PFIZER
$162,936
8.3
19
ONE TOUCH ULTRA
LIFESCAN
$156,340
1.7
20
JANUVIA
MERCK CANADA
$153,115
43.4
12/03/2013 8:14 AM
22 of 25
21
PLAVIX
BMS-SANOFI
$153,053
-54.9
22
LUCENTIS
NOVARTIS PHARMA
$150,073
54.9
23
ADVAIR
GLAXOSMITHKLINE
$144,477
5.5
24
ASCENSIA MICROFILL
BAYER HEALTHCARE
$132,020
4.9
25
CONCERTA
JANSSEN PHARMA
$130,362
13.8
26
APO-ESOMEPRAZOLE
APOTEX
$122,855
244.4
27
LIPITOR
PFIZER
$122,769
-12.6
28
CIALIS
LILLY
$117,492
8.4
29
OXYCONTIN
PURDUE PHARMA
$114,026
-55.6
30
OXYNEO
PURDUE PHARMA
$107,644
******
31
NASONEX
MERCK CANADA
$105,191
3.2
32
VIAGRA
PFIZER
$101,228
2.4
33
COPAXONE
TEVA
NEUROSCIENCE
$99,660
4.2
34
ADALAT XL
BAYER HEALTHCARE
$97,223
3.5
35
HYDROMORPH
CONTIN
PURDUE PHARMA
$96,268
15.1
36
REBIF
EMD CANADA
$94,614
-1.9
37
TEVA-VENLAFAXINE
XR
TEVA CANADA
$93,151
34
38
SEROQUEL XR
ASTRAZENECA
$92,094
19.1
39
PRADAX
BOEHRINGER ING
$91,546
156.9
40
TECTA
NYCOMED CANADA
$88,736
88.3
41
AVODART
GLAXOSMITHKLINE
$88,005
15.2
42
GLEEVEC
NOVARTIS PHARMA
$85,527
6.3
43
LANTUS SOLOSTAR
SANOFI-AVENTIS
$81,406
30.6
12/03/2013 8:14 AM
23 of 25
44
NEUPOGEN
AMGEN
$80,570
13.4
45
RAN-ATORVASTATIN
RANBAXY PHARMA
CAN
$76,454
-8.3
46
WELLBUTRIN XL
VALEANT PHARMA
$75,079
16.1
47
NOVORAPID
NOVO NORDISK
CDA
$74,312
11.6
48
LANTUS
SANOFI-AVENTIS
$73,472
20.1
49
ATRIPLA
BMS-GILEAD
$71,981
12.2
50
ACTONEL
WARNER CHILCOTT
$71,384
-25.7
51
FRAGMIN
PFIZER
$68,609
16.2
52
ARTHROTEC
PFIZER
$68,390
-1.1
53
TRUVADA
GILEAD SCIENCES
$67,897
13.3
54
TEVA-AMOXICILLIN
TEVA CANADA
$66,155
-13.1
55
ABILIFY
BMS PHARMA
$65,037
126.5
56
AVONEX
BIOGEN IDEC
$64,058
10.9
57
LEVEMIR
NOVO NORDISK
CDA
$63,333
14.2
58
ALESSE
PFIZER
$62,440
11.2
59
RATIOATORVASTATIN
TEVA CANADA
$62,420
90.6
60
EPIPEN
PFIZER
$62,143
3.9
61
RAN-RAMIPRIL
RANBAXY PHARMA
CAN
$61,331
3.3
62
HUMALOG
LILLY
$61,315
11.8
63
TEVA-OLANZAPINE
TEVA CANADA
$61,306
-13.9
64
PROMETRIUM
MERCK CANADA
$60,630
20.4
65
TIAZAC XC
VALEANT PHARMA
$58,647
0.4
12/03/2013 8:14 AM
24 of 25
66
VICTOZA
NOVO NORDISK
CDA
$58,589
95.3
67
CHAMPIX
PFIZER
$58,417
1.9
68
ARANESP
AMGEN
$57,868
0.1
69
TEVA-RABEPRAZOLE
TEVA CANADA
$57,203
-28.1
70
ACCU-CHEK AVIVA
ROCHE
DIAGNOSTICS
$57,143
104.6
71
BOTOX
ALLERGAN
$55,377
5.6
72
APO-LANSOPRAZOLE
APOTEX
$54,965
-15
73
MICARDIS
BOEHRINGER ING
$54,963
-43.9
74
RISPERDAL CONSTA
JANSSEN PHARMA
$54,803
-3.4
75
MYLAN-NIFEDIPINE
XR
MYLAN PHARMA
$54,787
-9.9
76
NEULASTA
AMGEN
$54,008
19.3
77
DETROL LA
PFIZER
$53,993
-1.4
78
SANDOSTATIN LAR
NOVARTIS PHARMA
$53,989
14
79
APO-OMEPRAZOLE
APOTEX
$53,429
-19.2
80
SINGULAIR
MERCK CANADA
$53,029
-50.1
81
TEVA-PANTOPRAZOLE
TEVA CANADA
$52,994
-1.8
82
RATIO-FENTANYL
TEVA CANADA
$52,947
83
STELARA
JANSSEN PHARMA
$52,735
22.7
84
EPREX
JANSSEN PHARMA
$52,088
-1.1
85
SIMPONI
JANSSEN PHARMA
$51,165
60
86
APO-RAMIPRIL
APOTEX
$49,829
-22.1
87
CESAMET
VALEANT PHARMA
$49,759
-27.9
12/03/2013 8:14 AM
25 of 25
88
RAN-PANTOPRAZOLE
RANBAXY PHARMA
CAN
$49,539
-6.2
89
ELAVIL
AA PHARMA
$49,506
11.6
90
MIRENA
BAYER HEALTHCARE
$49,476
16
91
VENTOLIN HFA
GLAXOSMITHKLINE
$48,788
-4.4
92
VYVANSE
SHIRE CANADA
$48,500
73.6
93
CELLCEPT
ROCHE
$48,366
-25.3
94
ATACAND PLUS
ASTRAZENECA
$48,299
-6.5
95
BIAXIN XL
ABBOTT EPD
$47,953
-10.2
96
KIVEXA
VIIV HEALTHCARE
UL
$47,461
6.2
97
RATIO-OXYCOCET
TEVA CANADA
$47,341
-3.7
98
ACCU-CHEK
COMPACT
ROCHE
DIAGNOSTICS
$47,123
-8.9
99
ADDERALL XR
SHIRE CANADA
$47,090
4.7
100
APO-AMLODIPINE
APOTEX
$46,894
-6.8
12/03/2013 8:14 AM

Top 100 Drugs in Canada

Caricato da

Informazioni sul documento

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

Top 100 Drugs in Canada

Caricato da

Copyright:

Formati disponibili

Canadian Healthcare Network

Top 100 Drugs

Prescription volume continued to increase in 2012, fueled by increased

About IMS Brogan

Generic substitution erodes brand prescription share

Top therapeutic classes

Canadian Healthcare Network

Click for larger view

Most prescribed products

Canadian Healthcare Network

Click for larger view

Prescription sales dollars

A history of the top five products

Abbott EPDs Synthroid (levothyroxine) is a prescription synthetic thyroid hormone that

Crestor (rosuvastatin), produced by AstraZeneca, is a member of the statin class for

Top generic products

Canadian Healthcare Network

routine general medical exam

normal pregnancy supervision

acute upper respiratory

Most prescribed by generic name

table 1. Top 100 Rx drugs

Canadian Healthcare Network

Canadian Healthcare Network

Canadian Healthcare Network

One Touch Ultra

Canadian Healthcare Network

Canadian Healthcare Network

table 2. Top 100 generic Rx products

Canadian Healthcare Network

Canadian Healthcare Network

Canadian Healthcare Network

Canadian Healthcare Network

Calcite 500+D 400

Canadian Healthcare Network

table 3. Top 100 Rx drugs (by generic name)

Canadian Healthcare Network

ETHINYL ESTRADIOL &

Canadian Healthcare Network

Canadian Healthcare Network

ETHINYL ESTRADIOL &

Canadian Healthcare Network

table 4. Top 10 classes

Canadian Healthcare Network

*Estimated volume of prescriptions dispensed in Canadian retail pharmacies.

Canadian Healthcare Network

Click for larger view

table 5. Top 100 products based on prescription dollars

Canadian Healthcare Network

ONE TOUCH ULTRA

Canadian Healthcare Network

Canadian Healthcare Network

Canadian Healthcare Network

Canadian Healthcare Network

Potrebbero piacerti anche